This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fuchs, B. Articles by Janknecht, R. Search for Related Content PubMed PubMed Citation Articles by Fuchs, B. Articles by Janknecht, R.

Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1 and May Represent an Independent Predictor of Survival in Ewing’s Sarcoma

Departments of¹ Biochemistry and Molecular Biology and ² Surgical Pathology, Mayo Clinic, Rochester, Minnesota

Purpose: Tumor markers ideally allow monitoring and prediction of disease progression. In Ewing’s sarcoma, a devastating childhood cancer, only a few reliable prognostic markers have been identified. To this end, we analyzed the expression of four tumor-promoting proteins, cyclin D1, HER2/Neu, Mdm2, and vascular endothelial growth factor (VEGF), in Ewing’s sarcoma.

Experimental Design and Results: Thirty-one tissue samples from patients with Ewing’s sarcoma were stained with antibodies against cyclin D1, HER2/Neu, Mdm2, or VEGF. Whereas no significant expression of HER2/Neu and Mdm2 was detected, positive cyclin D1 and VEGF staining was observed in 42% and 55% of all tumors, respectively. Importantly, VEGF expression was found to be an independent negative predictor of survival in Ewing’s sarcoma patients, whereas cyclin D1 expression did not correlate with survival in these patients. Consistently, the Ewing’s sarcoma-specific EWS-ETS oncoproteins were capable of activating both the cyclin D1 and VEGF promoters in transient transfections of tissue culture cells. Furthermore, this activation was enhanced by coexpression of the Sp1 transcription factor. Using a mammalian two-hybrid system, some evidence was obtained that this may involve a physical interaction between EWS-ETS and Sp1 proteins.

Conclusions: Our data reveal that VEGF may serve as a prognostic marker in Ewing’s sarcoma patients and provide a molecular mechanism by which VEGF and cyclin D1 expression is up-regulated in approximately half of all Ewing’s sarcomas.

This article has been cited by other articles:

				K. Kikuta, N. Tochigi, T. Shimoda, H. Yabe, H. Morioka, Y. Toyama, A. Hosono, Y. Beppu, A. Kawai, S. Hirohashi, et al. Nucleophosmin as a Candidate Prognostic Biomarker of Ewing's Sarcoma Revealed by Proteomics Clin. Cancer Res., April 15, 2009; 15(8): 2885 - 2894. [Abstract] [Full Text] [PDF]

				S. Sleijfer, W. T.A. van der Graaf, and J.-Y. Blay Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas Oncologist, November 1, 2008; 13(11): 1193 - 1200. [Abstract] [Full Text] [PDF]

				G. Sanchez, D. Bittencourt, K. Laud, J. Barbier, O. Delattre, D. Auboeuf, and M. Dutertre Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer PNAS, April 22, 2008; 105(16): 6004 - 6009. [Abstract] [Full Text] [PDF]

				Z. Zhou, K. Reddy, H. Guan, and E. S. Kleinerman VEGF165, but not VEGF189, Stimulates Vasculogenesis and Bone Marrow Cell Migration into Ewing's Sarcoma Tumors In vivo Mol. Cancer Res., November 1, 2007; 5(11): 1125 - 1132. [Abstract] [Full Text] [PDF]

				S. Shin, K. L. Rossow, J. P. Grande, and R. Janknecht Involvement of RNA Helicases p68 and p72 in Colon Cancer Cancer Res., August 15, 2007; 67(16): 7572 - 7578. [Abstract] [Full Text] [PDF]

				D. Kotilingam, D. C. Lev, A. J. F. Lazar, and R. E. Pollock Staging Soft Tissue Sarcoma: Evolution and Change CA Cancer J Clin, September 1, 2006; 56(5): 282 - 291. [Abstract] [Full Text] [PDF]

				J. Zou, H. Ichikawa, M. L. Blackburn, H.-M. Hu, A. Zielinska-Kwiatkowska, Q. Mei, G. J. Roth, H. A. Chansky, and L. Yang The Oncogenic TLS-ERG Fusion Protein Exerts Different Effects in Hematopoietic Cells and Fibroblasts Mol. Cell. Biol., July 15, 2005; 25(14): 6235 - 6246. [Abstract] [Full Text] [PDF]

				M. R. Verneris, A. Arshi, M. Edinger, M. Kornacker, Y. Natkunam, M. Karami, Y.-a. Cao, N. Marina, C. H. Contag, and R. S. Negrin Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells Clin. Cancer Res., June 15, 2005; 11(12): 4561 - 4570. [Abstract] [Full Text] [PDF]

				H. Guan, Z. Zhou, H. Wang, S.-F. Jia, W. Liu, and E. S. Kleinerman A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Inhibits Ewing's Sarcoma Growth in a Xenograft Mouse Model Clin. Cancer Res., April 1, 2005; 11(7): 2662 - 2669. [Abstract] [Full Text] [PDF]

				S. Dalal, A. M. Berry, C. J. Cullinane, D. C. Mangham, R. Grimer, I. J. Lewis, C. Johnston, V. Laurence, and S. A. Burchill Vascular Endothelial Growth Factor: A Therapeutic Target for Tumors of the Ewing's Sarcoma Family Clin. Cancer Res., March 15, 2005; 11(6): 2364 - 2378. [Abstract] [Full Text] [PDF]

				H. Guan, S.-F. Jia, Z. Zhou, J. Stewart, and E. S. Kleinerman Herceptin Down-Regulates HER-2/neu and Vascular Endothelial Growth Factor Expression and Enhances Taxol-Induced Cytotoxicity of Human Ewing's Sarcoma Cells In vitro and In vivo Clin. Cancer Res., March 1, 2005; 11(5): 2008 - 2017. [Abstract] [Full Text] [PDF]